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Background: Cancer treatment using gold (I) complexes is becoming popular. In this study, a gold (I) N-heterocyclic
complex designated as complex 3 was synthesized, its cytotoxicity was examined, and its anti-melanoma activity was
evaluated in vitro and in vivo.
Methods: Viability of cancer cells was determined by MTT assay upon treatment with various concentrations of a gold
(I) N-heterocyclic carbene complex (complex 3) in a dose and time dependent manner. Mouse melanoma cells B16F10
were selected for further apoptotic studies, including flowcytometric analysis of annexin binding, cell cycle arrest,
intracellular ROS generation and loss in the mitochondrial membrane potential. ELISA based assays were done for
caspase activities and western blots for determining the expression of various survival and apoptotic proteins.
Immunocytology was performed to visualize the translocation of p53 to the nucleus. B16F10 cells were inoculated
into mice and post tumor formation, complex 3 was administered. Immunohistology was performed to determine the
expressions of p53, p21, NF-κB (p65 and p50), MMP-9 and VEGF. Student’s t test was used for determining statistical
significance. The survival rate data were analyzed by Kaplan-Meier plots.
Results: Complex 3 markedly inhibited the growth of HCT 116, HepG2, and A549, and induced apoptosis in B16F10
cells with nuclear condensation, DNA fragmentation, externalization of phosphatidylserine, activation of caspase 3 and
caspase 9, PARP cleavage, downregulation of Bcl-2, upregulation of Bax, cytosolic cytochrome c elevation, ROS generation,
and mitochondrial membrane potential loss indicating the involvement of an intrinsic mitochondrial death pathway.
Further, upregulation of p53, p-p53 (ser 15) and p21 indicated the role of p53 in complex 3 mediated apoptosis. The
complex reduced tumor size, and caused upregulation of p53 and p21 along with downregulation of NF-κB (p65 and
p50), VEGF and MMP-9. These results suggest that it induced anti-melanoma effect in vitro and in vivo by modulating
p53 and other apoptotic factors.
Conclusions: The gold (I) N-heterocyclic carbene complex (C22H26N6AuO2PF6) designated as complex 3 induced
ROS and p53 dependent apoptosis in B16F10 cells involving the mitochondrial death pathway along with
suppression of melanoma tumor growth by regulating the levels of pro and anti apoptotic factors (p53, p21,
NF-κB, VEGF and MMP-9).
Keywords: Gold (I) N-heterocyclic carbene complex, Growth inhibition, Apoptosis, Melanoma, Tumor* Correspondence: joydevdinda@gmail.com; krishna@iicb.res.in
†Equal contributors
3School of Physical Sciences, ITM University, Turari, Jhansi Road, Gwalior,
MP 475001, India
1Cancer Biology and Inflammatory Disorder division, CSIR-Indian Institute of
Chemical Biology, Kolkata, West Bengal 700032, India
Full list of author information is available at the end of the article
© 2014 Nandy et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Nandy et al. Molecular Cancer 2014, 13:57 Page 2 of 14
http://www.molecular-cancer.com/content/13/1/57Background
The most widely used platinum-based anticancer drug
cisplatin has several limitations like neurotoxicity, nephro-
toxicity and development of resistance in some cancer
cells [1]. In order to overcome these limitations, different
metal complexes are being studied as anticancer agents.
Among these, metal N- heterocyclic carbene (NHC) com-
plexes are getting prominence as they readily fit the re-
quirements for an efficient drug design [2]. NHC ligands
are strong σ-donors as the free electron pairs of the
nitrogen donate to the free p-orbital of the carbene, which
reduces its π-backbonding capability [3]. This direct σ
coordination of the carbene carbon with the gold (I) atom
is responsible for its stability and biological activity. The
strong metal-carbenic bond of the NHC complex contrib-
utes to the tight binding kinetics, resulting in lesser ligand
dissociation [4]. Among various metal NHC complexes, sil-
ver NHC complexes have shown promise as anti-microbial
agents [5], whereas gold (I) NHC complexes are reported
to have anticancer activity on a number of cell lines [6].
There are a growing number of reports regarding the
cytotoxicity of gold (I/III) NHC complexes against breast
and prostate tumor cell lines [7].
The oxidation state I of gold has generated interest
because it enables a more stable complex coordination
which enhances its biological efficacy, the most popular
example being that of gold (I) phosphine complex aura-
nofin [8]. The complex, which was initially developed as
an anti-rheumatic agent, recently had its potentiality as an
anticancer agent well investigated [9]. As it is readily me-
tabolized by thiol biomolecules, the coordinated ligands
are mostly rendered impotent before the target enzyme is
reached [10]. Therefore the development of more stable
gold complexes with fine tuning of their ligands is of
particular interest [11]. With the NHC ligands showing
donor properties similar to those of phosphines, the
ease of systemic modifications of the NHC substituents
has made them attractive ligands for the development
of gold complexes as potential apoptotic agents against
cancer cells [12]. It may be mentioned that cancer cell
death through apoptosis is a desired goal. Apoptosis is
accompanied by chromatin condensation, DNA frag-
mentation, and phosphatidyl serine exposure to outer
membrane, and may be dependent on ROS and p53 levels
with the involvement of mitochondrial pathway or extrin-
sic pathway or both [13]. Tumour growth is governed by
the levels of NF-κB, p53, VEGF, MMP-9 etc. [14,15].
We had earlier reported the cytotoxicity of a gold (I)-N-
heterocyclic carbene complex with picoline functionalized
benzimidazolin-2-ylidene ligand on HeLa (human cervical
carcinoma), HepG2 (human hepatocellular carcinoma) and
B16F10 (mouse melanoma) cell lines [16]. We have now
synthesized and observed the cytotoxicity of another gold
(I) NHC complex, designated as complex 3, on a panel offour cancer cell lines including a highly metastatic mouse
melanoma cell line, B16F10 [17]. Using the B16F10 cell
line, we have examined the involvement of apoptosis after
treatment of complex 3. Next, the pathways of apoptosis
including the role of ROS and p53 were explored. We
have also determined the suppressive effect of complex 3
on B16F10 tumor growth in mice along with the status of
pro- and anti-tumor survival factors. Our study shows that
the gold complex 3 has potent anticancer activity towards
mouse melanoma.
Results
The Schiff base was synthesized by the reported procedure
[18] involving the reaction of pyridine 2-carboxaldehyde
with N-(2-aminoethyl) acetamide in dry ethanol. The proli-
gand 2 was synthesized from the corresponding Schiff base
1 by crusting with paraformaldehyde in dioxane followed
by addition of dilute HCl in diethyl ether as described in
a published procedure [19]. The layer separating from
dioxane was taken out using a separating funnel and was
mixed with minimum amount of water. Saturated solution
of KPF6 was added to the aqueous chloride salt to get
immediate precipitate of PF6 salt of 2. The formation of
imidazolium salt was confirmed by the appearance of imi-
dazolium CH2 proton signal (9.55 ppm) in NMR. Signal
for the proton bound to imidazolium-C2 appears at rather
low field indicating its relatively high acidity. Au-carbene
complex (3) formation [20] was supported by NMR spec-
troscopy; disappearance of the signal of the imidazolium-
C2 proton in the 1HNMR spectrum and downfield shift
(by 22.6 ppm) of the signal of carbenic carbon in 13C
NMR spectrum in comparison to proligand confirmed
the same. The carbenic carbon signal of 3 appears at
171.3 ppm (148.7 ppm for proligand) (Figure 1).
Schiff base, 1 has 1H NMR (CD3CN, 25°C, 400 MHz):
δ 7.89 (s, 1H, He), 7.76 (d, J = 6.3 Hz, 1H, Ha), 7.87 (d, J =
6.0 Hz, 1H, Hd) 7.05 (m, 2H, Hb,c), 5.03 (d, J = 6.0 Hz, 4H,
Hf,g), 3.33 (s, 1H, Hh), 2.48(s, 3H, Hi). 13C NMR (CD3CN,
100 MHz): δ 144.8, 139.0, 128.5, 123.8, 123.3, 117.4, 109.2,
32.2, 16.2. Anal. Calcd. For C10H13N3O (Additional file 1:
Figure S1), C, 62.82; H, 6.81; N, 21.99; Found C, 62.58; H,
6.66; N, 21.89%.
Proligand, 2 has 1H NMR (CD3CN, 25°C, 400 MHz):
δ 9.55 (s, 1H, Hj), 8.60 (d, J = 6.0 Hz, 1H, Ha), 8.10
(s, 1H, He), 7.87 (d, J = 6.0 Hz, 1H, Hd) 7.25 (m, 2H, Hb,c),
5.07 (d, J = 6.0 Hz, 4H, Hf,g), 3.33 (s, 1H, Hh), 2.48 (s, 3H,
Hi). 13C NMR (CD3CN, 100 MHz): δ 148.7, 145.7,
139.9, 129.2, 124.2, 123.6, 117.8, 109.4, 32.6, 32.8, 16.4
(Additional file 2: Figure S2). Anal. Calcd. For C11H14
N3OPF6, (Additional file 3: Figure S3) C, 37.82; H, 4.01; N,
12.03; Found C, 37.58; H, 4.03; N, 11.92%.
Gold-Complex, 3 has 1H NMR (DMSO-d6, 400 MHz,
30°C): δ 8.42 (d, J = 6.9 Hz, 1H, Ha), 7.81 (s, 1H, He),
7.59 (d, J = 8.1 Hz, 1H, Hi), 7.02 (t, J = 7.3 Hz, 1H, Hc),
Figure 1 Synthesis of the gold(I) N-heterocyclic carbene complex 3.
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Hh), 2.49 (s, 3H, Hi). 13C NMR (DMSO-d6, 100 MHz, 35°C)
δ 171.3, 149.5, 141.4, 129.6, 124.7, 124.0, 118.3, 109.8,
32.8, 32.9, 15.9 (Additional file 4: Figure S4). Anal. Calcd.
For C22H26N6AuO2PF6, (Additional file 5: Figure S5) C,
35.29; H, 3.47; N, 11.23; Found C, 35.16; H, 3.42; N, 11.18%.
Complex 3 induces apoptosis in B16F10 cells
The cytotoxic effect of complex 3 was investigated on
HCT 116, HepG2, A549 and B16F10 cells by MTT assay.
Treatment of different concentrations of complex 3 (0 to
50 μM) reduced the viability of the cancer cells in a dose
dependent manner (Figure 2A) in different degrees, with
higher toxicity in HCT 116 (GI50 4.73 ± 0.20 μM) after
24 h. It also showed good cytotoxic activity on the other
three cell lines, HepG2 (GI50 9.48 ± 0.25 μM), B16F10
(GI50 9.4 ± 0.26 μM) and A549 (GI50 13.71 ± 0.15 μM)
after 24 h. In a time dependent study, complex 3 (GI50
concentrations) induced 77% and 75% mortality in HCT
116 and HepG2 cells respectively, 67% mortality in
B16F10 cells and 60% mortality in A549 cells after 48 h
(Figure 2B and Additional file 6: Table S2). The commonly
used anticancer drug cisplatin had a marginally higher rate
of cytotoxicity as compared to 3 after 24 h (Figure 2C and
Additional file 6: Table S1). However, the proligand 2
failed to elicit any cytotoxicity in the cancer cell lines
mentioned in this study. Thus, complex 3 is a good cyto-
toxic agent against the cancer cells used in this study.
B16F10 is a highly metastatic form of a mouse melanoma
cell line [17]. Complex 3 showed significant cytotoxicity
towards this cell line like the other cancer cell lines used
in this study. Therefore B16F10 cells were used as modelfor further study on cytotoxicity induced by complex 3.
Cancer cell death through apoptosis is a desirable goal.
Complex 3 showed characteristic apoptotic changes in
morphology like cell shrinkage and rounding (Figure 2D,
upper panel), and nuclear changes such as chromatin
condensation and DNA fragmentation, seen using the nu-
clear staining dye AO along with EtBr and DAPI (Figure 2D,
middle panel and lower panel respectively). The number
of condensed bright fragmented nuclei seen in complex 3
treated cells after DAPI staining was higher, while yellow-
ish, orange and red colored nuclei or a combination of
these colored nuclei were observed upon staining with
AO/EtBr. Marked increase in the number of DNA frag-
ments in complex 3 treated cells as seen by using the DNA
fragmentation assay kit (Figure 2G) also corroborated the
findings in Figure 2D. Thus, cytotoxicity induced by com-
plex 3 in B16F10 cells may involve apoptosis.
Phosphatidylserine [PS] externalization from inner cell
membrane to outer membrane is a prerequisite for
apoptosis. Externalized PS can bind with annexin V [21].
B16F10 cells exposed to complex 3 showed higher percent-
age of annexin V-FITC binding cells after staining with
annexin V-FITC and PI. After 24 h of treatment with
10 μM of complex 3, percentage of apoptotic cells was
79.2% as compared to 3.9% in the vehicle treated cells
(Figure 2E). These findings suggested that complex 3 in-
duced death of B16F10 cells resulting from apoptosis.
Cell cycle arrest at various phases of cell division pre-
cedes apoptosis [13]. There was a gradual decrease in the
number of cells in G1 phase upon treatment with complex
3 (0 and 10 μM) for 24 h (Figure 2F). The percentage of
G0–G1 population for treated cells was 68.7% at 24 h as
Figure 2 (See legend on next page.)
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Figure 2 Growth inhibition and the subsequent evaluation of apoptosis of cancer cells in presence of complex 3. A, Percentage growth
inhibition of HCT 116, HepG2, A549 and B16F10, following treatment with complex 3 (0, 2.5, 5,10 and 25 μM) for 24 h. B, Percentage of growth
inhibition of HCT-116, HepG2, A549 and B16F10, following treatment with GI50 concentration of complex 3 for 0, 12, 24 and 48 h. C, Percentage
of growth inhibition of HCT-116, HepG2, A549 and B16F10, following treatment with cisplatin (0, 2.5, 5,10 and 25 μM) for 24 h. D, Morphological
images of the B16F10 cells treated with complex 3 (0 and 10 μM) in the upper row. Acridine orange/EtBr stained images of B16F10 cells treated
with complex 3 (0 and 10 μM) in the middle row. DAPI stained image of the B16F10 cells treated with complex 3 (0 and 10 μM) in the lower row. Scale
Bar = 10 mm. Magnification at 40×. E, Flow cytometric analysis of apoptosis induction in B16F10 cells treated with complex 3 (0 and 10 μM) for 24 h.
F, Cell cycle analysis of complex 3 (0 and 10 μM) treated B16F10 cells for 24 h. G, DNA fragmentation analysis of complex 3 (0, 2.5, 5, 10 and 25 μM)
treated B16F10 cells for 24 h. Values are mean ± S.D and represent one of the 3 representative experiments. *P < 0.05, **P < 0.01 and ***P < 0.001.
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decrease of 5.2% of cell population in the G0–G1 phase.
The percentages of S phase population for such cells
treated with complex 3 (0 and 10 μM) were 13.0% and
15.8% respectively indicating an increase in 2.8% of cell
population in the S phase after 24 h. Moreover, the
percentages of G2-M phase population for complex 3
(0 and 10 μM) treated B16F10 cells at 24 h were 13.0% and
15.4% respectively indicating an increase of 2.4% of cell
population in the G2-M phase. This indicated that com-
plex 3 may mediate cell cycle arrest at the G2-M phase.
Complex 3 induced apoptosis of B16F10 cells proceeds
via the mitochondrial death pathway involving ROS
“Apoptotic trigger” is initiated when the ratio of the
pro- and anti-apoptotic members of the Bcl-2 family is
unbalanced. Downregulation of the anti-apoptotic Bcl-2
protein and binding of pro-apoptotic Bax protein to the
mitochondria membrane cause disruption of the mito-
chondrial membrane leading to the release of cytochrome
c from mitochondria to cytosol. These events lead to the
activation of caspase 9 (initiator caspase) and caspase 3
(executioner caspase). Activated caspases induce the cleav-
age of PARP, thereby perturbing its ability for DNA repair
and leading to cell death [13]. Treatment of complex 3
suppressed the level of Bcl-2, activated Bax, lowered the
expressions of pro-caspase-3 and pro-caspase-9, promoted
PARP cleavage, and increased the level of cytosolic cyto-
chrome c in a dose dependent manner (Figure 3A). Densi-
tometric analyses of the western blots have been shown in
Figure 3B. Status of active caspase-3 and caspase-9, which
increased with doses of complex 3 as seen in the study
using assay kit (Figure 3C), were dampened upon pre-
incubation of cells with Z-LEHD-FMK and Z-DEVD-FMK
(Figure 3D). Moreover cells pre-incubated with Z-LEHD-
FMK and Z-DEVD-FMK exhibited higher cell viability as
compared to cells treated with either one or none of these
inhibitors prior to treatment with complex 3 (Figure 3E).
Elevated level of cytosolic cytochrome c was also observed
(Figure 3F) 24 h after complex 3 treatment (0 and 10 μM),
along with a dose dependent decrease in ΔΨm (Figure 3G).
Moreover, flowcytometric analysis of vehicle treated cells
revealed that 99.5% of the cell population exhibited fluor-
escence at the PE-Texas Red A channel indicating a higherlevel of cells having a healthy ΔΨm, whereas complex 3
(10 μM) treated cells revealed that 52.0% of the cell
population fluorescence at the PE-Texas Red A channel,
hinting at a loss of ΔΨm in 47.5% of cell population after
24 h (Figure 3H). These results indicate that complex 3
may induce apoptosis via the mitochondrial pathway.
Generation of reactive oxygen species (ROS) is a key
factor of apoptotic cell death. The maximum ROS gener-
ation was exhibited at 12 h after treatment of cells with
complex 3 (Figure 3I). Treatment with NAC (N-acetyl-
cysteine) 1 h prior to complex 3 treatment resulted in
decrease in ROS production (Figure 3J) along with in-
hibition of cell death (Figure 3K). Also, flowcytometric
analysis revealed that the FITC mean intensity was 410
in vehicle treated cells but 8829 in complex 3 (10 μM)
treated cells after 24 h, indicating a shift in FITC mean
intensity from the vehicle treated cells to the cells treated
with complex 3 (10 μM) (Figure 3L). However, incubation
with NAC 1 h prior to complex 3 (0 and 10 μM) treat-
ment resulted in a mean FITC mean intensity of 956 for
vehicle treated cells but 1928 for 3 (10 μM) treated cells
after 24 h, indicating a shift in intensity from the vehicle
treated cells to the cells treated with complex 3 (10 μM)
(Figure 3L). The study demonstrates that complex 3
induced apoptosis in B16F10 may proceed via the ROS
mediated pathway.
B16F10 cell death triggered by complex 3 results in p53
activation in ROS dependent manner
Apoptosis is generally regulated by p53. Therefore, the
role of complex 3 on p53 activation was examined. Treat-
ment of B16F10 cells with complex 3 (0, 5 and 10 μM)
resulted in upregulation of p53, p21 and phospho-p53
(p-p53) (Figure 4A). Treatment with 10 μM of complex
3 for 24 h resulted in increased translocation of p53 to
the nucleus along with increased expression of p21 as
compared to the untreated cells (Figure 4B). The corre-
sponding fluorescence intensity graphs have been provided
in a supplementary figure (Additional file 7: Figure S6).
Pretreatment of pifthrin-α (PFT-α), an inhibitor of p53
transactivation, inhibited the expression of p21 along
with reduction in the level of p53 dependent proteins
such as Bax and cytosolic cytochrome c. However, PFT-α
failed to downregulate the expression of p-p53 (ser 15)
Figure 3 Elucidation of the ROS mediated, mitochondrial death
pathway upon caspase activation. A, Expression of various
apoptotic proteins following treatment of cells with complex 3 for
24 h, with β-Actin as loading control. B, Densitometric analysis of
proteins detected by Western blot. C, Determination of caspase 9
and 3 activities at 405 nm, following treatment of cells with complex
3 for 24 h. D, Determination of caspase 9 and 3 activities at 405 nm
in cells, incubated 1 h with Z-LEHD-FMK and Z-DEVD-FMK prior to
treatment with complex 3 for 24 h. E, Percentage of growth inhibition
of cells following incubation with caspase inhibitors Z-LEHD-CHO and
Z-DEVD-CHO (for caspase 9 and caspase 3 respectively), along with
complex 3 for 24 h. F, Cytochrome c release into the cytosol after
treatment of cells with complex 3 as determined at 450 nm assay.
G, Loss of Δψm of complex 3 treated cells after 24 h. H, Flowcytometric
analysis of loss of Δψm in presence of complex 3 after 24 h. I, ROS
generation upon treatment of complex 3 for 6, 12 and 24 h at 529 nm.
J, ROS generated in cells treated with complex 3 and with varying
concentrations of NAC (0.2, 1, 5 and 10 μM) after 24 h at 529 nm.
K, Percentage growth inhibition of cells in presence or absence of either
complex 3 or NAC or in presence of both of them. L, Flowcytometric
analysis ROS generation in cells following treatment with complex 3
along with NAC after 24 h. Values are mean ± S.D and represent one of
the 3 representative experiments. *P < 0.05, **P < 0.01 and ***P < 0.001.
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(Figure 4C-D). Also, pretreatment with PFT-α prevented
growth inhibition of cells treated with complex 3 (Figure 4E).
Therefore p53 may play a significant role in complex 3
mediated apoptosis of B16F10 cells.
Treatment of B16F10 cells with NAC 1 h prior to
complex 3 addition led to the inhibition of p53 as well as
p-p53 (phosphorylated at ser-15) (Figure 4F). However,
treatment of PFT-α failed to suppress ROS production
(Figure 4G), indicating that p53 may not be involved in
ROS generation whereas ROS maybe involved in p-p53
up regulation.
Complex 3 exhibits antitumor activity in B16F10 melanoma
model
Complex 3 administered intraperitoneally at the dosages
of 5, 10, 20, and 40 mg/kg body weight per day till the
60th day showed 100% survivability for dosages of 0, 5
and 10 mg/kg, 80% survivability with 20 mg/kg, and 70%
survivability with 40 mg/kg body weight respectively
(Figure 5A). Administration of complex 3 (0, 5 and
10 mg/kg body weight/day) was started from 15th day
onward since the day of injection of B16F10 cells in the
mice and was continued till the 23rd day. The mice were
sacrificed on the 24th day (Figure 5B).
Mice bearing the B16F10 tumor but not administered
complex 3 faced total mortality by the 40th day, whereas
treatment with 5 and 10 mg/kg mouse body weight of
the complex ensured 30% and 70% survivability till the
60th day (Figure 5C). Dose dependent decrease in the
tumor size was observed following treatment with complex
3 (0, 5 and 10 mg/kg of mouse body weight) (Figure 5D).
Haematoxylin and Eosin staining revealed an increase in
Figure 4 Evaluation of the status of p53 following treatment of cells with complex 3. A, Upregulation of p53, p-p53 (ser 15) and p21.
B, Upregulation of p53, p21 and subsequent nuclear translocation of p53 upon treatment of cells with complex 3 (0 and 10 μM). Scale Bar = 15 mm.
Magnification at 40×. C-D, Expression profile of p53 and p-p53 (ser 15) along with the downregulation of p21, Bax and cytosolic cytochrome c upon
treatment with 15 and 30 μM of pifthrin-α in presence of complex 3 (10 μM) after 24 h. β-Actin was used as a loading control. E, Percentage growth
inhibition of cells in presence of pifthrin-α (0, 5, 15 and 30 μM) and complex 3 (10 μM) with respect to the control (cells without treatment with
complex 3). F, Down regulation of p53 and p-p53 (ser 15) in the presence of NAC. β-Actin was used as a loading control. G, ROS generation as
determined at 529 nm of cells treated with complex 3 (10 μM) in the presence of PFT-α (0, 5, 15, 30 μM). Values are mean ± S.D and represent one
of the 3 representative experiments. *P < 0.05 and **P < 0.01.
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(Figure 5G). Both mitotic index (an indication of cell prolif-
eration) and tumor weight decreased upon treatment with
complex 3 (Figure 5H-I). Body weight remained nearly
constant (Figure 5E), but the tumor volume decreased in
a dose dependent manner (Figure 5F). The results show
that complex 3 is a potent suppressor of melanoma tumor.
Translocation and localization of p53/p21, NF-kB p50/p65,
VEGF and MMP-9 proteins in tumor as determined by
immunohistological analysis
The p53 protein expression and translocation to the nu-
cleus was upregulated along with the upregulation of
p21 in the tumor sections of the mice administered with
complex 3 (10 mg/kg body weight of mice) with respect
to the tumors sections of the mice not administered
complex 3 (Figure 6, upper panel). The translocation of
the anti-apoptotic NF-κB protein (p65 and p50) was
inhibited upon administration of complex 3 (10 mg/kgbody weight of mice) (Figure 6, middle panel). Following
treatment with complex 3 (10 mg/kg body weight of mice),
the expressions of angiogenic and metastatic markers
such as VEGF and MMP-9 respectively were also inhibited
(Figure 6, lower panel), indicating that tumor death occurs
by activation of p53 and inhibition of the NF-κB protein,
VEGF and MMP-9. The corresponding fluorescence
intensity graphs have been provided as a supplementary
figure (Additional file 8: Figure S7).
Discussion
Our study revealed that complex 3 showed appreciable
cytotoxicity towards a panel of four cancer cell lines (HCT
116, HepG2, A549 and B16F10) after 24 h, but in different
degrees, with the GI50 being comparable to that of cisplatin.
Interestingly, 15 μM of cisplatin was toxic to the peripheral
mononuclear blood cells (PBMCs), whereas complex 3
up to 80 μM did not show any toxicity (Additional file 6:
Table S3). This was in accordance with earlier reports
Figure 5 (See legend on next page.)
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Figure 5 B16F10 cell induced tumor growth in BALB/c mice in the presence or absence of complex 3. A, Mice toxicity survival curve upon
administration of various doses of complex 3. B, Treatment series depicting the sequence followed for complex 3 administration, following tumor
growth. C, Percentage survival of tumor carrying mice upon administration of complex 3 (0, 5, 10 mg/kg body weight of mice) over a period of
60 days. D, Tumor size variation upon administration of complex 3 (0, 5, 10 mg/kg body weight of mice). E-F, body weight (g) and tumor volume
(cm3) of mice administered with complex 3 (0, 5 and 10 mg/kg weight of mice). G-I, H/E staining (→ depicting the intact and fragmented nuclei
in the control and the treated tumor sections respectively), tumor weight (g) and mitotic index of tumors excised from mice administered with
complex 3 (0, 5 and 10 mg/kg body weight). The survival rate data were analyzed by Kaplan-Meier plots. Values are mean ± S.D and represent
one of the 3 representative experiments . *P < 0.05 and **P < 0.01.
Figure 6 The expression profile of tumor promoting and inhibiting proteins of tumor sections excised out from tumor bearing mice
administered with complex 3 (0 and 10 mg/kg/body weight of mice). Immunohistochemical analysis of p53/p21 (upper panel), NF-қB
p65/p50 subunits (middle panel), and VEGF/MMP9 (lower panel). Magnification at 20×. Scale Bar = 15 mm.
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heterocyclic carbene complexes towards non transformed
cell lines with respect to cisplatin [22]. Earlier, Rubbiani
et al. and Wang et al. had reported the efficacy of other
gold (I) NHC complexes on MCF-7, HT-29, HepG2 and
U-87MG which resulted in increased AnnexinV-FITC
binding, ROS generation, loss of ΔΨm, along with eleva-
tion of Bax, p53, p-p53 (ser 15), p21, cleaved PARP and
cleaved caspase 3 [4,23], thereby supporting the results
obtained following treatment of B16F10 with complex 3.
Moreover, inhibition of caspase 9 and caspase 3 with
Z-LEHD-FMK (caspase 9 inhibitor) and Z-DEVD-FMK
(caspase 3 inhibitor) generally decreased the growth
inhibitory potential of complex 3. This indicates that
complex 3 may initiate apoptosis via the mitochondrial
death pathway.
The role of p53 is quite essential here. The inhibition
of p53 transactivation by pifthrin-α (PFT-α) led to a
down regulation of its transcriptional targets such as
p21 and Bax. p-p53 (ser 15) is a marker for DNA dam-
age, occurring mainly due to excessive ROS generation.
However PFT-α failed to inhibit the expression of p-p53,
thereby indicating that ROS acted upstream of p53 fol-
lowing complex 3 treatment. However, p21 and Bax be-
ing the transcriptional targets of p53 were affected by
the inhibitory role of PFT-α on p53 as a transcription
factor. As Bax translocation to the mitochondria results
in the release of cytochrome c in the cytosol, inhibition
of Bax expression inhibited the release of cytochrome c
into the cytosol. Also treatment with PFT-α, 1 h prior to
treatment with complex 3 did not induce growth inhibition.
This implies that complex 3 may induce apoptosis by in-
volvement of p53.
Generation of ROS upon induction of apoptosis by gold
(I) NHC complex has been already reported [4]. When
cells were pre-incubated with NAC (a ROS scavenger),
there was an increase in cell viability in presence of
complex 3, along with down regulation of p53 and p-p53
(ser 15). However, pre-incubation with PFT-α did not pre-
vent ROS generation. Thereby, complex 3 may induce
ROS generation upstream of p53 and induce apoptosis via
ROS mediated pathway. Therefore, we may conclude
that complex 3 mediates apoptosis in B16F10 cells via a
ROS mediated mitochondrial death pathway involving
p53 up regulation.
One suggested mode of anticancer activity of gold (I)-
NHC complexes is by accumulation in the mitochondria
leading to ΔΨm perturbations and by the prevention of
the catalytic activity of the selenoenzyme thioredoxin re-
ductase (TrxR), which in turn induces extensive oxidation
of thioredoxins (Trxs) [24]. In the light of this report, we
suggest that complex 3 may induce apoptosis in B16F10
cells by mitochondrial accumulation and inhibition of the
catalytic activity of thioredoxin reductase.Yan et al. had reported that a cyclometalated gold (III)
complex with an N-heterocyclic carbene ligand induced
suppression of PLC tumor in mice at a dosage of 10 mg/kg
body weight [25]. Similarly we observed that treatment of
male BALB/c mice bearing B16F10 tumor with complex 3
(5 and 10 mg/kg of mice body weight) induced decrease in
tumor size, volume, and weight as well as in mitotic index,
with an increase in fragmented nuclei in a dose dependent
manner with respect to the control without any deleterious
effect on the health of the animal. Treatment of such
mice with complex 3 (10 mg/kg body weight) showed
up regulation of p53 and p21 expression, which was also
observed in case of B16F10 cells treated in vitro by complex
3. These findings indicate that complex 3 may mediate
B16F10 cell growth inhibition via up regulation of p53
and p21. Auranofin has been reported to down regulate
NF-κB and VEGF [26,27]. Administration of complex 3
(5 mg/kg body weight of mice) resulted in down-
regulation of NF-κB along with VEGF and MMP-9. Our
results thereby indicate that the antitumor activity of com-
plex 3 may be mediated by upregulation of p53 and p21,
and downregulation of NF-κB p65 and p50 subunits along
with VEGF and MMP-9.
The gold complex induced ROS and p53 dependent
apoptosis in B16F10 cells involves the mitochondrial death
pathway. Complex 3 suppressed melanoma tumor growth
by regulating the level of pro anti apoptotic factors (p53,
p21, NF-κB, VEGF and MMP-9). Also, it was cytotoxic on
three cell lines like HCT 116, HepG2 and A549 examined
in our study. So it may be a good anticancer agent at least
towards some other cancer cells and tumors.
Materials and methods
Reagents
Dulbecco’s modified Eagle medium (DMEM), fetal bovine
serum (FBS), penicillin, streptomycin, neomycin (PSN)
antibiotic, trypsin and ethylene di-amine tetra-acetic acid
(EDTA) were obtained from Gibco BRL (Grand Island,
NY, USA). Tissue culture plastic wares were obtained from
NUNC (Roskilde, Denmark). Antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Organic
solvents used were of HPLC grade. All other chemicals in-
cluding doxorubicin, NAC used were from Sigma Chem.
Co. (St. Louis, MO, USA) or mentioned otherwise.
Synthesis of the Schiff base 2-pyridyl-N-(2-ethylacetamido)
methylamine (1)
Pyridine-2-carboxaldehyde (450 mg, 4.21 mmol) and N-
acetylethylenediamine (429 mg, 4.21 mmol) were taken in
dry ethanol (25 ml) and refluxed under stirring condition
for 6 h. Volatiles were removed under reduced pressure
and dried under vacuum. Analytically pure samples were
obtained after crystallization by slow diffusion of diethyl
ether into chloroform solution of Schiff base. The solid
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2.86 mmol).Synthesis of proligand 2-pyridin- N-(2-ethylacetylamido)-2-yl-
2H-imidazo [1, 5-a] pyridin-4-ylium hexafluorophosphate (2)
2-Pyridyl-N-(2-ethylacetoamido) methylamine 1 (450 mg,
2.36 mmol) and crushed 91% paraformaldehyde powder
(75.6 mg, 2.70 mmol) were taken in 20 ml of dioxane and
stirred for 4 h to form a slurry; then the mixture was
refluxed for 10 h. A 5 ml aliquot of 2 (N) HCl in diethyl
ether was added slowly to the cold slurry, resulting in
immediate separation of layers - a lower layer of a yellow-
ish red viscous liquid and a colorless liquid in the upper
part. Then 5 ml water was added to the solution and the
aqueous phase was separated by a separating funnel.
Excess saturated aqueous KPF6 was added to the solution
and immediately a white precipitate was obtained. This
precipitate was then filtered out and recrystallized from
acetonitrile and diethyl ether. The resultant solid mass
was dried in vacuum and the yield was 66% (542 mg,
1.55 mmol).Preparation of gold (I) N- heterocyclic carbene complex 3
Proligand 2 (200 mg, 0.57 mmol) and silver oxide (67.2 mg,
0.29 mmol) were dissolved in acetonitrile (15 ml) and the
mixture was stirred for 5 h. The volume of the solution
containing a silver carbene complex was reduced to
5 ml. In 5 ml acetonitrile solution of AuSMe2Cl (85.4 mg,
0.29 mmol), the silver carbene complex was added drop
wise, and immediately a white precipitate was observed.
The mixture was filtered; the volatiles were removed
under reduced pressure and dried under vacuum. Analyt-
ically pure sample of a gold (I) carbene complex 3 was
obtained after crystallization by slow diffusion of diethyl
ether into an acetonitrile solution of complex 3. Yield was
80% (173.5 mg, 0.23 mmol).Cell culture
Cell lines, such as HCT-116 (human colorectal carcinoma),
HepG2 (human hepatocellular carcinoma), A549 (human
non small lung carcinoma) and B16F10 (mouse melanoma),
were obtained from National Centre for Cell Science, Pune,
India. These cell lines were cultured in DMEM supple-
mented with 10% FBS and 1% antibiotic (PSN) and in-
cubated at 37°C in a humidified atmosphere with 5% CO2.
After achieving 75–80% confluence, cells were harvested
with 0.025% trypsin and 0.52 mM EDTA in phosphate
buffered saline (PBS) and were seeded at desired density
to allow them to re-equilibrate a day before the start of
experimentation. All experiments were conducted in
DMEM supplemented with 10% FBS and 1% antibiotic
(PSN) solution.Cell viability assay
Cells were treated with various concentrations of complex 3
(0, 2.5, 5, 10, 25 and 50 μM) dissolved in 0.05% of DMSO
for 24 h and their respective GI50s were determined. More-
over, viability of cells treated with the GI50 concentrations
of complex 3 (determined after 24 h) for 12, 24, 36 and
48 h were determined by MTT assay as described earlier
[28]. In another set of experiments, cells treated with
cisplatin (0, 2.5, 5, 10, 25 and 50 μM) for 24 h were
taken as positive control. Absorbance of the solubilized
intracellular formazan was measured at 595 nm using an
ELISA reader (Model: Emax, Molecular device, USA).
Assessment of cellular death parameters under a microscope
B16F10 cells treated with complex 3 (0 and 10 μM) for
24 h were viewed under a phase contrast microscope.
Cells were stained with DAPI (4′, 6-diamidino-2-pheny-
lindole) for the detection of chromatin condensation and
DNA fragmentations. Cells were stained with acridine or-
ange (A/O) and ethidium bromide (EtBr) to distinguish
between live and apoptotic death. Cells were observed
under an inverted phase contrast/fluorescent microscope
(Model: OLYMPUS IX70, Olympus Optical Co. Ltd.,
Shibuya-ku, Tokyo, Japan) and images were acquired.
Detection of apoptosis using flow cytometry
Apoptosis was assayed by using an annexin V-FITC apop-
tosis detection kit (Calbiochem, La Jolla, CA) as described
earlier [21]. B16F10 cells treated with complex 3 (0 and
10 μM) for 24 h were stained with PI and annexin V-FITC
according to manufacturer’s instructions. The percentage
of live, apoptotic and necrotic cells were analyzed by BD
LSRFortessa cell analyzer (Becton Dickinson, San Jose,
CA, USA). Data from 106 cells were analyzed for each
sample.
Analysis of DNA fragmentation by ELISA
B16F10 cells were treated with complex 3 (0, 2.5, 5, 10
and 25 μM) for 24 h and fragmented DNA was assayed
by an ELISA based method as earlier described [13].
Analysis of cell cycle arrest
Cell cycle arrest was analyzed by treating cells with
complex 3 (0 and 10 μM) for 24 h followed by PI staining,
as described earlier [13]. The percentages of cell population
undergoing cell cycle arrest at various stages of mitosis
were analyzed by BD LSRFortessa cell analyzer (Becton
Dickinson, San Jose, CA, USA). Data from 106 cells were
analyzed for each sample.
Caspase-3 and 9 activity assay
B16F10 cells were treated with complex 3 (0, 2.5, 5, 10
and 25 μM) for 24 h and caspase-3 and caspase-9 activ-
ities were quantified with commercially available caspase-
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Research Products, Mountain View, CA) as described
earlier [13]. Caspase activity was spectrophotometrically
detected at 405 nm on an ELISA reader (Model: Emax,
Molecular device, USA). In another set of experiments,
B16F10 cells were treated with 10 μM of Z-DEVD-FMK
(caspase-3 inhibitor) and Z-LEHD-FMK (caspase-9 inhibi-
tor) 1 h prior to treatment with complex 3 (0 and 10 μM)
and MTT assay was done to evaluate growth inhibition of
cells.Measurement of intra cellular ROS level upon treatment
of complex 3 on B16F10 cells
For the detection of intracellular ROS generation, B16F10
cells treated with complex 3 (0 and 10 μM) for 24 h were
incubated with 10 μM of H2DCFH-DA (2′, 7′-dichloro-
fluorescein diacetate, Molecular Probes) with or without
NAC (N-acetyl-cysteine, added 1 h prior to complex 3
treatment) for 25 min at 37˚C, following which cells were
analyzed by BD LSRFortessa cell analyzer. Data from 106
cells were analyzed for each sample as described earlier
[13]. In another set of experiments, B16F10 cells treated
with complex 3 (0, 2.5, 5, 10 and 25 μM) for 6, 12 and
24 h were incubated with 10 μM of H2DCFH-DA for
25 min at 37°C. The increase in fluorescence due to
production of ROS was noted (excitation 488 nm, emission
529 nm) using a fluorimeter. In another set of experiment,
cells were incubated with NAC (0, 2.5, 5, 10 and 25 mM),
1 h prior to treatment with complex 3 (10 μM) for 24 h
and the fluorescence increase because of production of
ROS was noted (excitation 488 nm, emission 529 nm)
using a fluorimeter. Further, MTT assay was done on cells
incubated with NAC (0 and 10 mM) prior to addition of
complex 3 (0 and 10 μM) for 24 h.Measurement of mitochondrial membrane potential
To measure mitochondrial membrane potential (MMP),
B16F10 cells treated with complex 3 (0 and 10 μM) for
24 h were incubated with JC-1(5,5′,6,6′-tetrachloro-1, 1′,
3, 3′-tetraethylbenzimidazolylcarbocyanine iodide, Sigma).
The reagent gives fluorescence in the FITC channel for
green monomers in case of healthy cells having high mito-
chondrial membrane potential and in the PE-Texas Red A
channel for red aggregates signifying apoptotic cells indi-
cating a drop in the mitochondrial membrane potential.
Data from 106 cells were analyzed in a BD LSRFortessa
cell analyzer for each sample.
Moreover, B16F10 cells treated with complex 3 (0, 2.5, 5,
10 and 25 μM) for 24 h were incubated with Rhodamine
123 and the fluorescence emission was measured in a
spectrofluorometer (LS50B; PerkinElmer) using fluorescence
intensity at 535 nm as described earlier [29].Measurement of cytosolic cytochrome c
B16F10 cells were treated with complex 3 (0, 2.5, 5, 10
and 25 μM) for 24 h, and the level of cytosolic cytochrome
c was determined by a cytochrome c colorimetric assay
kit, as described earlier [13].
Confocal microscopy for Immunocytochemistry studies
B16F10 cells were treated with complex 3 (0 and 10 μM)
for 24 h and confocal microscopy for immunocytochem-
istry analysis of p53 and p21 was done as reported earlier
[13]. Cells were observed under an Andor spinning disk
confocal microscope and images were acquired.
Western blot analysis of protein expression in B16F10
cells following treatment with complex 3
Western blotting of the lysates of the cells treated with
complex 3 (0, 2.5, 5 and 10 μM) for 24 h was performed
using 10–15% SDS-PAGE gels, primary antibodies, alka-
line phosphatase conjugated secondary antibodies and
NBT-BCIP as a chromogenic substrate as described earlier
[30]. The experiments were done for the detection of
PARP cleavage and for determining expression levels of
pro-caspase 3 and pro-caspase 9 along with cytosolic cyto-
chrome c and Bax. The expressions of p53, p-p53 (ser 15),
p21 and Bax were determined in cells treated with complex
3 (0, 5 and 10 μM) for 24 h. In another set of experiments,
cells were pretreated with 15 and 30 μM of the p53 trans-
activation inhibitor pifthrin-α (PFT–α), then treated with
complex 3 (10 μM) for 24 h and analyzed for the level of
expressions of p53, p21, Bax and cytochrome c. MTT
assay was conducted to determine the growth inhibitory
action of complex 3 (0 and 10 μM) in presence of PFT-α
(0, 5, 15 and 30 μM). Also cells treated with NAC (0, 5
and 10 mM) for 1 h and then treated with complex 3
(10 μM) for 24 h were analyzed for the level of p53 and
p-p53 (ser 15) expression.
Tumor Induction and evaluation of the antitumor activity
of complex 3 in mice
In order to select the least toxic doses, male BALB/c mice
were administered (i.p.) with 0, 5, 10, 20 and 40 mg/kg
body weight of complex 3, observed for 60 days, and inoc-
ulated with B16F10 cells as described earlier [31]. Briefly,
mice inoculated with 5 × 104 B16F10 cells in the right hind
limb (subcutaneously) were monitored for 15 days, after
which complex 3 (5 and 10 mg/kg mouse body weight)
was administered by intraperitoneal (i.p.) injection. The
final dose was given on the 23rd day and the mice were
sacrificed on the 24th day. Care and maintenance of animals
were done in adherence to the guidelines of the Institu-
tional Animal Care and Use Committee.
After sacrifice, the tumors were excised out and H/E
slides were prepared. Mitotic index of the tumors of mice
administered with complex 3 (5 and 10 mg/kg of mice
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the B16F10 cell induced tumor only. Along with tumor
weight, tumor volume, body weight and the survival index
of the mice were determined.
Immunohistological analysis of the tumor proteins
Slides fixed in 4% paraformaldehyde were incubated with
primary antibodies for p53, p21, NF-κB p65 and p50,
VEGF and MMP-9 overnight at 4°C. After washing with
1X TBST, slides were incubated with secondary antibodies
for the above proteins for 2 h and stained with DAPI for
identification of the nucleus. Cells were observed under
an Andor spinning disk confocal microscope and images
were acquired.
Statistical analysis
All the experiments were carried out in triplicate and
values were reported as mean ± SD. Student’s t test was used
for determining statistical significance (P < 0.05, P < 0.01
and P < 0.001). The survival rate data were analyzed by
Kaplan-Meier plots.
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